Crinetics Pharmaceuticals/$CRNX
Crinetics falls after reporting Q1 net loss of $127.8M and reiterating GAAP opex guidance of $600–650M for 2026.
19 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Ticker
$CRNX
Sector
Primary listing
Employees
594
Headquarters
Website
CRNX Metrics
BasicAdvanced
$4bn
-
-$5.13
-
-
Price and volume
Market cap
$4bn
52-week high
$57.99
52-week low
$25.83
Average daily volume
1.3m
Financial strength
Current ratio
18.603
Quick ratio
18.245
Long term debt to equity
3.226
Total debt to equity
3.737
Profitability
EBITDA (TTM)
-541.617
Gross margin (TTM)
-1,744.78%
Net profit margin (TTM)
-2,747.18%
Operating margin (TTM)
-3,020.32%
Effective tax rate (TTM)
-0.04%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-24.69%
Return on equity (TTM)
-39.17%
Valuation
Price to revenue (TTM)
200.803
Price to book
3.08
Price to tangible book (TTM)
3.08
Price to free cash flow (TTM)
-8.649
Free cash flow yield (TTM)
-11.56%
Free cash flow per share (TTM)
-4.334
Growth
Revenue change (TTM)
2,277.50%
Earnings per share change (TTM)
34.34%
3-year revenue growth (CAGR)
61.56%
3-year earnings per share growth (CAGR)
16.14%
What the Analysts think about CRNX
Analyst ratings (Buy, Hold, Sell) for Crinetics Pharmaceuticals stock.
CRNX Financial Performance
Revenues and expenses
CRNX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Crinetics Pharmaceuticals stock?
Crinetics Pharmaceuticals (CRNX) has a market cap of $4B as of May 09, 2026.
What is the P/E ratio for Crinetics Pharmaceuticals stock?
The price to earnings (P/E) ratio for Crinetics Pharmaceuticals (CRNX) stock is 0 as of May 09, 2026.
Does Crinetics Pharmaceuticals stock pay dividends?
No, Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders as of May 09, 2026.
When is the next Crinetics Pharmaceuticals dividend payment date?
Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals (CRNX) does not currently have a Beta indicator.